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Background: In Africa, accessing eye health services is a major challenge. Ocular surface squamous neoplasia
(OSSN) is a substantial ocular health problem in Africa related to solar UV light exposure and HIV infection among
other risk factors. The disease causes visual loss and even death in advanced cases. This study was conducted to
assess referral pathway and treatment delay for patients with OSSN in Kenya.
Methods: Adults with conjunctival lesions presenting to four eye centres were asked about their occupations,
when they noticed the growth, health facilities visited in seeking care, cost of consultation, surgery, medicines and
histopathology and dates at each step. The time-to-presentation was divided into quartiles and correlates analysed
using ordinal logistic regression.
Results: We evaluated 158 first-time presenters with OSSN. Most were women (102 [65%]), living with HIV (78/110
tested [71%]), with low to medium income (127 [80%]). Most of the HIV patients (49/78 [63%]) were in antiretroviral
care programs. About half (88/158, [56%]) presented directly to the study centres while the rest were referred.
Indirect presenters sought care earlier than direct presenters (median 2.0 months vs 5.5 months) and travelled a
shorter distance to the first health facility (median 20 km vs 30 km) but had surgery later (median 12.5 months vs 5.
5 months). Visits beyond the first health facility for indirect presenters markedly increased delay (median 7.3, 29.0,
37.9, and 32.0 months for 1–4 facilities, respectively). Delay was associated with number of health facilities visited
(adjusted ordered OR = 9.12; 95%CI 2.83–29.4, p < 0.001) and being female (adjusted ordered OR = 2.42; 95%CI 1.
32–4.44, p = 0.004). At the time of presentation at the study centres for surgery the median tumour diameter in
both directly and indirectly presenting patients was 6 mm (p = 0.52) and the histological spectrum of OSSN was
similar between the groups (p = 0.87).
Conclusions: Referral delays definitive treatment for OSSN. Women were more likely to experience delay. Despite
regular contact with the health system for those with known HIV infection, delays occurred. Early detection and
referral of OSSN in the HIV service might reduce delays, but reassuringly delay did not give rise to a larger
proportion with more advanced grade of OSSN.
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Ocular surface squamous neoplasia (OSSN) usually pre-
sents as a defined lesion of the conjunctiva and/or cor-
nea. In temperate countries it presents as a rare, slow-
growing tumour mostly affecting elderly men. In con-
trast, in sub-Saharan Africa (SSA) OSSN is more com-
mon than in other global regions (1.38 and 1.18 cases/
100000/year in males and females respectively in Africa
vs 0.18 and 0.08 cases/100,000/year in males and females
respectively worldwide). It is also more aggressive in
SSA, predominantly affects people living with HIV
(PLWH), and occurs with similar frequency in men and
women [1, 2]. A study from Kenya found that people
with no formal education were at higher risk of OSSN
and presented with larger tumours than more educated
individuals [3]. Late presentation with large tumours and
orbital spread is not uncommon in Africa [4–6]. Surgery
is the mainstay of treatment and if it is provided in a
timely manner, outcomes can be very good with very
low recurrence rates [7].
The Kenya health care referral system is organized into
six levels [8]. The first level comprises community units.
Services here focus on health promotion and treatment
of minor ailments. Dispensaries form the second level.
The third level comprises health centres with basic out-
patient care, minor surgical services, basic laboratory
services, maternity care, and limited inpatient facilities.
They also coordinate the community units under their
jurisdiction. Levels 4 and 5 are secondary-care hospitals
providing curative services, and some training centres.
Level 6 are tertiary referral facilities that offer specialised
care and training to health workers. There are also a
number of private and mission hospitals.
In Africa, accessing eye health services is a major chal-
lenge. A study in the Kibera slums and Dagoretti area of
Nairobi found that the main barriers to utilization of eye
health services were a lack of a perceived need for treat-
ment (49% of respondents), lack of money (33% of re-
spondents), while a small proportion (8%) did not know
where to obtain help [9]. A study from Tanzania found
that for eye trauma cases an injury at the weekend, use
of topical treatment, and visiting other facilities were in-
dependently associated with delay of more than 24 h in
accessing specialist eye care. Circular journeys were
common where patients repeatedly visited health facil-
ities that were unable to treat the injury [10].
Cancer is a growing problem in Africa. The age-
standardised incidence rates for most cancers increased
by more than 10% in most African countries between
1990 and 2013 [11]. A literature review of current cancer
prevention approaches revealed that the major impedi-
ments to good care include a lack of awareness, limited
human and financial resources, limited vaccine use (with
regard to human papilloma virus), inadequacy of cancerregistries, fear, cultural reasons (such as examination by
doctors of the opposite sex) and competing health de-
mands [12]. A study from Rwanda examined health sys-
tem delays in breast cancer presentation and diagnosis
of more than 6 months and found that low levels of edu-
cation and consulting a traditional healer before a nurse
or doctor were the main predictors of delay after adjust-
ing for sociodemographic and clinical characteristics
[13]. Visiting 5 or more health facilities before the diag-
nosis was associated with even longer delay in that
study. The experiences of breast cancer, Kaposi’s sar-
coma and lymphoma patients in the only oncology
centre in Cameroon show that 35% of patients waited
>6 months after the first sign of disease before present-
ing to the health system, while diagnosis was made
>3 months after presentation in 47% of cases [14]. In the
Cameroon study the total delay between first sign of
cancer and a correct diagnosis was >6 months for 63%
of patients. There is limited data on access to eye cancer
services. This study was conducted to describe the pres-
entation and referral “journey” that OSSN patients travel
in Kenya, describing the time spent, identifying the
points of delay and determining the factors associated
with delay.
Methods
This study was conducted in Kenya between July 2012
and July 2014. We used Ministry of Health records to
identify four eye centres that performed the highest
number of conjunctival excision biopsies between 2008
and 2011. The centres were Kenyatta National Hospital
in Nairobi, PCEA Kikuyu Eye Unit (25 km from Nairobi
in Central Kenya), Kitale district hospital in the north
Rift Valley (490 km from Nairobi) and Sabatia Eye Hos-
pital (300 km from Nairobi) in the western highlands
bordering Lake Victoria. These centres receive referrals
from surrounding health facilities.
We prospectively recruited consecutive adult patients
(≥18 years) presenting to the four centres with any con-
junctival lesion (first presentation or recurrence) sus-
pected to be OSSN and scheduled for surgical excision.
A detailed history was taken using a structured ques-
tionnaire before surgery. Participants were asked when
they had first noticed the ocular lesion. To document
the referral route taken prior to presentation, partici-
pants were asked to list the health facilities they had vis-
ited, their location, dates visited, advice given and total
cost of clinical care to the patient (consultation, tests,
surgery and medications). The first facility the patient
visited was denoted as Facility 1, the second one visited
(either as a result of formal referral or self-initiated re-
ferral) was denoted Facility 2 and so on. A comprehen-
sive clinical examination was conducted at the slit lamp,
including measurement of the longest lesion diameter
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went surgical excision under local anaesthesia. A histo-
pathologist examined all the tissue specimens at MP
Shah Hospital laboratory, Nairobi. Individuals who had
histologically confirmed OSSN were offered a HIV test;
if this was positive they were offered a referral for care
and a CD4 count test. The detailed description of clin-
ical assessment, surgery, tissue handling and testing have
been previously published [3].
Treatment “delay” was defined as the time between
awareness of having tumour lesion and having surgery at
the study centre. For the purpose of this analysis we only
included individuals who had histologically confirmed
OSSN. As recurrence after a prior excision is likely to
influence health-seeking behaviour and the journey
followed, we excluded those with recurrent lesions from
this analysis.
Data on the other health facilities visited by patients
prior to presentation to one of the four study centres (lo-
cation, health system level, ownership etc.) were obtained
from the Kenya Ministry of Health web-based master fa-
cility list (http://kmhfl.health.go.ke/#/home) accessed on
15th November 2015. Information about the availability of
ophthalmic surgical facilities (eye operating theatre) at
each of these other health facilities was obtained from the
Kenya Ministry of Health, Department of Ophthalmic Ser-
vices (DOS). One-way distances travelled by road from
the patients’ home town to the various health facilities
and study centres were estimated using Google Maps fol-
lowing the roads that public vehicles would use.
We compared patients who presented directly to one of
the four centres (“direct presenters”) with those who had
visited other health facilities prior to presenting to a study
centre (“indirect presenters”). Characteristics of the two
groups were compared using the chi-squared test for pro-
portions, and the t-test or Mann-Whitney U-test as appro-
priate for continuous variables. We traced the care seeking
journey to describe the time taken, and the advice given at
each stage. To investigate factors associated with delayed
presentation we subdivided the total time in the range from
awareness to surgery into quartiles and created an ordered
categorical outcome variable. Ordinal logistic regression
was used to estimate odds ratios (OR) and 95% confidence
intervals (95%CI).
The likelihood ratio test was used to assess which fac-
tors from the univariable analysis would be included in
the multivariable regression model. Variables that were
associated with delay at a level of p < 0.1 in the univari-
able model were included in an initial multivariable
model. The final multivariable model included variables
which were independently associated with the out-
come (p < 0.05). All statistical analyses were per-
formed using Stata version 12.1 (StataCorp, College
Station, Texas, USA).Results
A total of 500 individuals with conjunctival lesions were
enrolled in this study and underwent surgical excision.
Of these, 191 (38.2%) were diagnosed with OSSN by
histopathology. Among these, 158 (83%) had new lesions
and 33 (17%) had recurrent lesions (at least one prior
excision at the same site).
The care-seeking journey of the 158 patients with new
lesions was analysed: 88 (55.7%) presented directly to
study centres and 70 (44.3%) presented indirectly via
one or more other health facilities (Fig. 1). Overall, the
mean age was 41.9 years (SD 12.0) and the majority were
females (102 [65%]). Education levels were variable, 125
(79%) had completed primary school or above, and 67
(42%) had completed secondary school. The majority
worked mostly outdoors (101 [65%]). Most occupations
were low or middle income in nature (127 [80%]) and
were predominantly in the agricultural sector. HIV status
and CD4 count were obtained for patients who returned
after surgery (110 [70%]. Of these, 78 (71%) were HIV
positive, of whom 49 (63%) were already on antiretro-
viral therapy (ART).
The numbers of individuals taking different routes to
the study centres and the time spent along each stage on
the care-seeking journey is illustrated in Fig. 1. Most in-
direct presenters (56, [80%]) visited one other health fa-
cility before going to the study centres. Overall, despite
having a shorter time to first presentation, indirect pre-
senters took longer to receive surgery than direct pre-
senters (5.5 vs 9.6 months, p = 0.001). The additional
time in getting from the first health facility to the study
centre was largely responsible for this difference. The
longest delay in the whole care pathway occurred when
patients went from the first facility to a second one (me-
dian 6.1 months, IQR 3.1–12.2). Referral beyond the first
facility markedly increased delay.
The demographic and clinical characteristics of partic-
ipants, by type of presentation, are shown in Table 1.
There was little evidence of a difference between direct
and indirect presenters by age, marital status, education,
occupation, past experience of receiving eyecare or HIV
status. There was weak evidence that indirect presenters
were more likely to be female than direct presenters
(71% vs 59%; p = 0.11). There was evidence that the
main presenting symptom was different (p = 0.03) be-
tween the two groups, with pain more common in the
direct presenters (17.1% vs 2.9%). At the time of presen-
tation at the study centres for surgery the median
tumour diameter in both directly and indirectly present-
ing patients was 6 mm (p = 0.52) and the histological
spectrum of OSSN was similar between the groups
(p = 0.87). Kikuyu Eye Unit and Kenyatta National Hos-
pital had a significantly larger proportion of referrals
than the other two study centres (p < 0.001). Direct
Fig. 1 The care-seeking journey followed by 158 new OSSN patients and the duration of each step
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facility (study centre) than indirect presenters (median
30 km vs 20 km, p = 0.003).
The median cost of care was similar in the two groups
at 3800 (IQR 3800–4800) Kenyan Shillings (KSh) for dir-
ect presenters and 3880 (IQR 3800–4100) KSh for indir-
ect presenters. The exchange rate in May 2016 was 100
KSh to 1US$. Costs incurred along the indirect route
were mainly a subsidised consultation fee charged in
government hospitals as most of the participants studieddid not receive surgery there plus the cost at the study
centre. Costs at the study centres (including consult-
ation, surgery, post-operative medication and histopath-
ology) were: Kikuyu Eye Unit 3800KSh, Kenyatta
National Hospital 4000KSh, Sabatia 4800 KSh and Kitale
3500 Ksh. All histology was done at MP Shah Hospital
to reduce inter-observer variation in the diagnosis. Tis-
sue specimens from Sabatia and Kitale hospitals were
sent to Nairobi for histopathology using a courier service
which added to the costs.
Table 1 Demographic and clinical characteristics of 158 OSSN patients presenting directly or indirectly to study centres
Demographic or clinical feature Direct presenters N = 88 Indirect presenters N = 70 p-valuea
n (%) n (%)
Age in years, mean (SD), y 42.5 (12.0) 41.1 (12.0) 0.47c
Sex, No. (%) 0.11
Male 36 (40.9) 20 (28.6)
Female 52 (59.1) 50 (71.4)
Marital status, No. (%) 0.21
Single 16 (18.2) 9 (12.9)
Married 55 (62.5) 49 (70.0)
Divorced or Separated 3 (3.4) 6 (8.6)
Widowed 14 (15.9) 6 (8.6)
Highest education level, No. (%) 0.25
Completed secondary or higher 33 (37.5) 34 (48.6)
Completed primary or some secondary 33 (37.5) 25 (35.7)
None or some primary 22 (25.0) 11 (15.7)
Location of primary occupation, No. (%) 0.66
Indoor 29 (33.0) 26 (37.1)
Outdoor 57 (64.8) 44 (62.9)
Missing data 2 (2.2) 0 0
Employment 0.23
Unemployed/no regular income 5 (5.7) 8 (11.4)
Low to middle income 69 (78.4) 58 (82.9)
High income 10 (11.4) 4 (5.7)
Missing data 4 (4.6) 0 0
HIV infection/ART use, No. (%) 0.42
HIV- 15 (25.0) 17 (34.0)
HIV+/ART- 15 (25.0) 14 (28.0)
HIV+/ART+ 30 (50.0) 19 (380)
CD4 count in cells/mm3, median(IQR) 344 (148–802) 219 (120–670) 0.42d
HIV-associated immunodeficiency by CD4 count in cells/mm3, No. (%) 0.28
None or not significant (≥500) 15 (37.5) 14 (34.2)
Mild (350–499) 5 (12.5) 3 (7.3)
Advanced (200–349) 9 (22.5) 5 (12.2)
Severe (<200) 11 (27.5) 19 (46.3)
Main symptom, No. (%) 0.03
Lump 53 (60.2) 48 (68.6)
Pain 15 (17.1) 2 (2.9)
Redness 6 (6.8) 8 (11.4)
Others 14 (15.9) 12 (17.1)
Tumour diameter in mm, median(IQR) 6.0 (4.3–8.5) 6.0 (4.2–10.0) 0.52d
Histopathology, No. (%) 0.87
CIN I (mild dysplasia) 5 (5.7) 4 (5.7)
CIN II (moderate dysplasia) 13 (14.8) 9 (12.9)
CIN III (severe dysplasia) 19 (21.6) 13 (18.6)
Carcinoma-in-situ 0 0 1 (1.4)
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Table 1 Demographic and clinical characteristics of 158 OSSN patients presenting directly or indirectly to study centres (Continued)
SCC – poorly differentiated 1 (1.4) 1 (1.4)
SCC – moderately differentiated 45 (51.1) 35 (50.0)
SCC – well differentiated 5 (5.7) 7 (10.0)
Study Centre, No. (%) <0.001
Kikuyu Eye Unit 42 (47.7) 55 (78.6)
Kenyatta National Hospital 4 (4.6) 9 (12.9)
Sabatia Eye Hospital 25 (28.4) 3 (4.3)
Kitale District Hospital 17 (19.3) 3 (4.3)
Distance from home to study centre or to 1st health facility in km, median(IQR)b 30 (20–89) 20 (5–56) 0.003 d
Cost of care in KSh, median (IQR) 3800 (3800–4800) 3880 (3800–4100) 0.01d
Abbreviations: ART – antiretroviral therapy; CIN – conjunctival intraepithelial neoplasia; SCC- squamous cell carcinoma; KSh – Kenyan shillings
atesting whether the distribution of each demographic feature is the same in direct and indirect presenters
b1 patient had missing data on distance, 48 missing data on HIV and 77 on CD4 count
ct-test with unequal variances
dMann-Whitney U-test
Gichuhi et al. BMC Health Services Research  (2017) 17:485 Page 6 of 11The level of the health facility and the availability of an
operating theatre at the place where patients presenting
indirectly first went to are shown in Table 2. For 24 pa-
tients it was not possible to determine whether surgical
facilities were available, mostly because the patient could
not correctly name the facility.
The most common points of entry into the health
system for indirect presenters were at level 5 county
referral hospitals (22 [31.4%]) and private clinics (13
[18.6%]). It is noteworthy that for the majority of fa-
cilities an operating theatre was available (37 [53%]).
All four of the study centres have a dedicated oph-
thalmic operating theatre.
The advice given to indirectly presenting patients at
the other facilities is shown in Table 3.
At each point patients were referred, advised to re-
attend for follow up or advised to have surgery. It is not
clear why some health facilities with operating theatres
did not offer surgery. Regardless of the advice, all pa-
tients eventually went to the study centres at various
time points. From the first facility visited, 32 patientsTable 2 Types of health facilities represented by Facility 1 in the car
Health facility Operating theatre available
None General theatre
Dispensary or Health Centre 1 0
District or sub-district hospital 0 3
County referral hospital 0 5
Private clinic 2 0
Mission hospital 0 1
Outreach eye camp 6 0
Facility not identified 0 0
TOTAL, N (%) 9 (12.9) 9 (12.9)
NOTE: This shows where indirect presenters first entered the health system and the
operating theatre that is shared by all departments. Eye unit theatre means the eyewere formally referred to a study centre. Of these, 29
(91%) followed this advice and went directly to a
study centre within a median of 2.3 months (IQR
1.2–3.9), while three patients went via other clinics
first and reached a study centre at 1, 3 and
42 months. Out of the 31 advised to re-attend for fol-
low up, only one returned to the same facility seven
months later and was then referred to one of the
study centres for surgery. The other 30 either self-
referred to a study centre (20 [65%]) and received
surgery with a median time of 6.1 months (IQR 3.0–
11.9) or to another clinic (10 [32%]). The five who
were advised to have surgery all went to the study
centres within a median (IQR) duration of 5.6 (2.3–
11.5) months.
There was a modest linear relationship between dur-
ation of symptoms and the lesion size (Fig. 2) for direct
presenters (p = 0.01), but not indirect presenters
(p = 0.41). For the direct presenters, those who pre-
sented later tended to have a larger lesion, with an ex-
pected increase in size of 0.09 mm per month (95% CIe-seeking journey for indirect presenters
TOTAL
Eye unit theatre Unknown n (%)
0 5 6 (8.6)
- 2 5 (7.1)
17 0 22 (31.4)
8 3 13 (18.6)
3 2 6 (8.6)
0 0 6 (8.6)
0 12 12 (17.1)
28 (40.0) 24 (34.3) 70 (100.0)
availability of operating theatres in those clinics. General theatre refers to an
unit has its own operating theatre
Table 3 Advice given at each health facility along the indirect care-seeking journey
Step in journey Advice given Total patients seen
Follow up n(%) Surgery Offered n(%) Referred n(%)
Facility 1 31 (44.3) 5 (7.1) 32 (45.7) 70 a
Theatre available 13 4 18 37
No theatre 1 0 2 3
missing information 17 1 12 30
Facility 2 3 (21.4) 2 (14.3) 9 (64.3) 14
Theatre available 1 1 7 9
No theatre 0 0 1 1
missing information 2 1 1 4
Facility 3 1 (33.3) 1 (33.3) 1 (33.3) 3
Theatre available 0 0 1 1
No theatre 0 0 0 0
missing information 1 1 0 2
Facility 4 0 0 1 (100) 1
Theatre available 0 0 0 0
No theatre 0 0 0 0
missing information 0 0 1 1
aData on advice given was only available for 70 patients. There was missing data on the advice given to 2 patients at the first facility
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between symptom duration and tumour size was dif-
ferent in direct and indirect presenters (p = 0.33).
Delay was associated with larger tumour size at pres-
entation (OR 1.07, 95%CI 1.01–1.13, p = 0.02). The
median (IQR) tumour diameter was 5.6 (4.2–7.0), 5.0
(4.2–7.1), 6.4 (4.2–11.5) and 7.6 (5.4–10.0) millimetrescoeff=0.03, 95%CI(-0.05, 0.11) p=0.4
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Fig. 2 Scatterplots showing tumour size against delay between tumour aw(mm) in the following delay categories; 0.4–3.2, 3.3–
7.0, 7.1–15.6 and 15.7–190.5 months respectively. Of
the 158, 15 developed recurrences at one year, 7/88
(8.0%) from the direct group and 8/70 (11.4%) from
the indirect group (p = 0.46). The recurrence rate
was therefore not worse in either group. A sub-group
analysis of indirect presenters comparing those who1 coeff=0.09, 95%CI (0.03, 0.16) p=0.01
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areness to surgery (months)
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facilities before the study centres did not show any
significant differences (Additional file 1: Table S1).
Analysis of the predictors of delay is shown in
Table 4. On multivariable ordered logistic regression,
the number of health facilities visited in the care
pathway followed and being female are associated
with increased delay. Participants who followed an in-
direct path were twice as likely to be in a higher
delay group than those in the direct pathway (ad-
justed OR = 2.3, 95%CI 1.5–3.7; p < 0.001). Similarly,
females were twice as likely to be in a higher delayTable 4 Predictors of delay in presentation of 158 new patients with
Factor 0.4–
3.2 months
(N = 38)
3.3–
7.0 months
(N = 41)
7.1–
15.6 months
(N = 40)
Distance from home (in 10 km units) to
first health facility or study center,
mean(SD)
7.1 (10.2) 6.3 (8.2) 4.3 (5.0)
Total cost of care (in 100Ksh units), mean
(SD)
41.0 (6.0) 40.0 (5.0) 42.2 (15.9)
Care pathway followed, No (%)
Direct 27 (30.7) 25 (28.4) 19 (21.6)
1 facility visited 11 (19.6) 15 (26.8) 18 (32.1)
2 or more facilities visited 0 1 (7.1) 3 (21.4)
Sex, No. (%)
Male 18 (32.1) 18 (32.1) 12 (21.4)
Female 20 (19.6) 23 (23.6) 28 (27.5)
Age, mean(SD) y 42 (13.0) 40 (11.8) 46 (13.6)
Marital status, No. (%)
Single 2 (8.0) 11 (44.4) 3 (12.0)
Married 28 (26.9) 24 (23.1) 31 (29.8)
Divorced or Separated 1 (11.1) 5 (55.6) 1 (11.0)
Widowed 7 (35.0) 1 (5.0) 5 (25.0)
Highest education level, No. (%)
Completed secondary or higher 14 (20.9) 19 (28.4) 15 (22.4)
Completed primary or some secondary 12 (20.7) 16 (27.6) 14 (24.1)
None or some primary 12 (36.4) 6 (18.2) 11 (33.3)
Occupation, No. (%)
High income 3 (21.4) 3 (21.4) 6 (42.9)
Low-Medium income 31 (24.4) 35 (27.6) 30 (23.6)
Unemployed 4 (30.8) 3 (23.1) 3 (23.1)
HIV infection & ART use, No. (%)a
HIV- 11 (34.4) 10 (31.3) 6 (18.8)
HIV+/ART- 6 (20.7) 11 (37.9) 8 (27.6)
HIV+/ART+ 11 (22.5) 9 (18.4) 12 (24.5)
Main symptom, No. (%)
Lump 24 (23.8) 24 (23.8) 29 (28.7)
Pain 7 (41.2) 5 (29.4) 2 (11.8)
Redness 4 (28.6) 4 (28.6) 2 (14.3)
Others 3 (11.5) 8 (30.8) 7 (26.9)
a There were 48 participants with missing HIV/ART datagroup than males (adjusted OR = 2.1; 95% CI 1.15–
3.81, p = 0.02).
Discussion
This study identified various challenges along the jour-
ney to treatment for new patients with OSSN. Firstly, re-
ferral significantly delayed surgery and delay was
associated with larger tumours at the time of surgery.
Patients in the indirect route initially presented earlier
than those who went directly to study centres perhaps
because it was a shorter distance and the cost of care
was lower. However, surgery was more delayed in theOSSN, sub-divided into quartiles
15.7–
190.5 months
(N = 39)
Univariate ordered
proportional OR (95%
CI)
p- value Adjusted ordered
proportional OR
(95% CI)
p- value
6.6 (9.6) 0.99 (0.95–1.02) 0.53 −
42.9 (8.4) 1.01 (0.99–1.04) 0.32
<0.001 <0.001
17 (19.3) 1.00 (REF) 1.00 (REF))
12 (21.4) 1.56 (0.85–2.83) 1.38 (0.75–2.54)
10 (74.1) 12.93 (3.79–44.06) 13.03 (3.78–44.94)
0.01
8 (14.3) 1.00 (REF) − 1.00 (REF)
31 (30.4) 2.29 (1.27–4.15) 0.006 2.31 (1.25–4.24)
39 (8.3) 0.99 (0.97–1.02) 0.69 −
0.59 −
9 (36.0) 1.00 (REF)
21 (20.2) 0.60 (0.28–1.31)
2 (22.2) 061 (0.17–2.26)
7 (35.0) 0.81 (0.27–2.45)
0.23 −
19 (28.4) 1.00 (REF)
16 (27.6) 1.01 (0.54–1.89)
4 (12.1) 0.55 (0.26–1.17)
0.95 −
2 (14.3) 1.00 (REF)
31 (234) 0.96 (0.37–2.48)
3 (23.1) 0.82 (0.21–3.12)
0.07 −
5 (15.6) 1.00 (REF)
4 (13.8) 1.41 (0.58–3.40)
17 (34.7) 2.57 (1.13–5.88)
1.07 (0.94–1.21) 0.32
24 (23.8)
3 (17.7)
4 (28.6)
8 (308)
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9.6 months, p = 0.001), particularly if the patients visited
more than one health facility. This correlates well with
the finding that the number of facilities visited before
was an important predictor of delay in receiving surgery.
When definitive treatment was carried out in the study
centres, there was no significant difference in the
tumour size nor the histological spectrum of OSSN was
similar between the direct early presenting and the indir-
ect delayed presenting groups (p = 0.87).
Secondly, we found being female was another import-
ant predictor of delay. Gender disparities in access to
health care services have also been identified in East Af-
rica for other ocular diseases such as eye trauma and
cataract with females having relatively more difficulty
[10, 15]. A study on access to cataract surgery in
Tanzania found that some women needed to seek per-
mission from their husbands before going to hospital or
may rather put up with the adversity of poor eye health
for fear of being seen as a burden in the family [15].
Women are less likely than men to be the financial deci-
sion makers with regard to seeking health care in this
population. In addition, they may have other responsibil-
ities to consider before going to hospital such as child
care and home upkeep. Although there is limited infor-
mation on gender-specific utilization of cancer services
in Africa, particularly for OSSN, we hypothesize that
women with household and child-care responsibilities
have more difficulty attending health facilities, particu-
larly if distant referrals are made.
With respect to the patients reported advice and
treatment provided at facilities other than the four
study centres there is an intrinsic limitation in that
we do not know how many other (if any) people had
excisions in the other health facilities who never came
to one of the study centres. There is no reporting of
this to the central Ministry of Health. However, it
would appear that advising follow up for suspicious
lesions needs to be supported by more than just a
clinical impression. At the first health facility level, 20
of 31 patients who were advised to return for follow
up went to the study centres and had surgery within
median 6 months (mean 13 months) and were found
to have OSSN (Table 3). Only one patient at the first
facility took the follow up advice and by the time of
review seven months later was referred for surgery
and was found to have OSSN. While we have no in-
formation on how the lesions looked at earlier time
points, they may have appeared either benign or were
suspicious of malignancy and progressed rather rap-
idly within a few months, underscoring two things,
that OSSN in East Africa is an aggressive disease and
that distinguishing OSSN from benign lesions clinic-
ally is challenging as they can look very similar [3].It is still unclear what drives the decision to present to
a first health facility once the person become aware of
the tumour. Perhaps it is more the absolute size rather
than the rate of growth or combination of the two. We
found only a modest difference in growth rates between
direct and indirect presenters. It is likely that the dur-
ation and growth rates will vary. Pain maybe an import-
ant driver of the decision; we found that pain was more
common among the direct presenters (p = 0.02).
The majority of participants were living with HIV and
were already in contact with HIV care and treatment
programs. Despite this, they still experienced delay.
There could be various explanations for this. Firstly,
awareness about OSSN among HIV health workers may
be limited. Secondly, patients on ART may find it par-
ticularly challenging to seek care for OSSN. Over half
(44/81 [54%]) the patients on ART had advanced or se-
vere immunosuppression and thus at high risk for co-
morbidities such as tuberculosis [16]. Thirdly, due to
stigma around HIV they may not feel safe or comfort-
able in other health facilities. A recent study in rural
western Kenya found that cervical cancer stigma was
highly correlated with HIV stigma (correlation coeffi-
cient 0.72) [17].
We did not find income or level of formal education a
barrier to presentation despite most of our patients
(80%) being in the low to medium income group. The
majority worked in farming. Most employment (83%)
nationwide is in the informal sector so it is difficult to
know the real earnings as they are not captured in tax
systems [18]. In Kenya half of healthcare expenditure
(51.1%) is paid for out-of-pocket [19]. The gazetted
monthly basic minimum wages for the agricultural in-
dustry during the study period was an average of KSh
5704 in 2012 rising to KSh 6503 in 2013 and remained
the same in 2014 which was comparable to the fees
charged at the study centres [20]. However the oppor-
tunity cost of lost income during the care-seeking period
for the patient and other adults involved in supporting
this care could not be estimated. A study in Kenya found
that households spend over 10% of their annual income
on healthcare payments with the poor spending more
than 33% [21]. The mean annual total spending per
household (both inpatient and outpatient) was KSh
16,000 (£114) in urban areas and KSh 5600 (£40) in
rural areas. Only about 7% of Kenyans have private
health insurance [20]. The National Health Insurance
Fund (NHIF) run by the government is the dominant in-
surance provider. The maximum contribution was KSh
320 (about £2) per month until April 2015 when it was
increased to KSh 1700 (£12) per month. NHIF used to
pay for the inpatient bed charge only, therefore day sur-
gery (the norm for OSSN surgery) would not be covered.
This situation has now been reviewed. The cost of travel
Gichuhi et al. BMC Health Services Research  (2017) 17:485 Page 10 of 11is not captured in this analysis. Usually most patients in
Kenya would travel to hospitals accompanied by a rela-
tive or friend, further increasing the cost of care.
This study had several weaknesses. Data on tumour
awareness, cost of care and referral details were obtained
from a structured questionnaire before surgery rather than
medical records from referring facilities. The question-
naire, while practical, may not be the most accurate tool
to evaluate care-seeking behaviour. The responses were
subject to recall bias. We also did not capture all past ex-
periences in receiving eyecare to see if this affected care-
seeking behaviour. The analysis did not address the reli-
ability of the initial diagnosis in the indirect presenters
nor the availability of eye surgeons or other surgeons
skilled enough and adequately equipped with the right
surgical instruments to excise conjunctival lesions as a
cause of referral and hence delay. These data were not
available to us. The presence or absence of an operating
theatre is probably not the determining factor for referral
- it is likely to be the availability of an appropriately skilled
surgeon. Our analysis of the flow through the health sys-
tem did not address why the patients did what they did.
To answer this would require a qualitative study.Conclusions
Women and those who visited more health facilities were
at increased risk of delay. We observed various health sys-
tem delays. Referral beyond the first point of contact was a
major cause of delay. Reassuringly delay did not give rise to
a larger proportion with more advanced grade of OSSN. It
is also unclear why patients who are in regular contact with
the health system through HIV care programs have delayed
presentation. There is need to evaluate if health education
about OSSN and the ocular effects of HIV infection par-
ticularly among HIV care workers is a barrier to the
provision of timely intervention. Systematic OSSN screen-
ing could be considered in HIV care programs. Patients
with pain presented more rapidly. The cost to the patient
of treating OSSN (excluding transport casts) was equivalent
to a month’s wages. It has been suggested that cancer care
programs could learn from HIV programs by mainstream-
ing cancer into the health system together with advocacy
and improved health worker training [22].Additional file
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